Related references
Note: Only part of the references are listed.Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer
Michael B. Streiff et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Efficacy and safety of rivaroxaban compared to enoxaparin in treatment of cancer-associated venous thromboembolism
Benjamin Simmons et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
Annie M. Young et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Gary E. Raskob et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Resolve conflicting rankings of outcomes in network meta-analysis: Partial ordering of treatments
Gerta Ruecker et al.
RESEARCH SYNTHESIS METHODS (2017)
Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report
Clive Kearon et al.
CHEST (2016)
International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer
Dominique Farge et al.
LANCET ONCOLOGY (2016)
Spotlight on advances in VTE management: CALLISTO and EINSTEIN CHOICE
Miriam Bach et al.
THROMBOSIS AND HAEMOSTASIS (2016)
Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed?
Alok A. Khorana et al.
THROMBOSIS RESEARCH (2016)
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial
Gary E. Raskob et al.
LANCET HAEMATOLOGY (2016)
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
Brian Hutton et al.
ANNALS OF INTERNAL MEDICINE (2015)
Ranking treatments in frequentist network meta-analysis works without resampling methods
Gerta Ruecker et al.
BMC MEDICAL RESEARCH METHODOLOGY (2015)
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer A Randomized Clinical Trial
Agnes Y. Y. Lee et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
Gary H. Lyman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial
G. Agnelli et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials
Martin H. Prins et al.
LANCET HAEMATOLOGY (2014)
CANCER-ASSOCIATED THROMBOTIC DISEASE Treatment of cancer-associated thrombosis
Agnes Y. Y. Lee et al.
BLOOD (2013)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
A Randomised Open-Label Trial Comparing Long-term Sub-Cutaneous Low-Molecular-weight Heparin Compared with Oral-Anticoagulant Therapy in the Treatment of Deep Venous Thrombosis
A. Romera et al.
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY (2009)
Recurrent thromboembolism and major bleeding during oral anticoagulant therapy in patients with solid cancer: findings from the RIETE registry
Paolo Prandoni et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer
Russell D. Hull et al.
AMERICAN JOURNAL OF MEDICINE (2006)
Secondary prevention of venous thromboembolic events in patients with active cancer: Enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period
Steven R. Deitcher et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2006)
Malignancies, prothrombotic mutations, and the risk of venous thrombosis
JW Blom et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer
AYY Lee et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
P Prandoni et al.
BLOOD (2002)
Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer - A randomized controlled study
G Meyer et al.
ARCHIVES OF INTERNAL MEDICINE (2002)
Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis
P Lopez-Beret et al.
JOURNAL OF VASCULAR SURGERY (2001)
Risk factors for deep vein thrombosis and pulmonary embolism -: A population-based case-control study
JA Heit et al.
ARCHIVES OF INTERNAL MEDICINE (2000)
Share Paper
